Latest filing published 08 Mar 2023 for Arcutis Biotherapeutics, Inc., €9,911.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David W. Osborne: trading record in brief
David W. Osborne, listed as senior executive, appears in our data through filings on Arcutis Biotherapeutics, Inc. shares, published by SEC (Form 4). The record holds 17 filings, for trades running from 4 February 2020 to 6 March 2023.
Sales make up the whole of the open-market record (12 sales, €938k). Outside the open market, there are 4 share grants. 2023 to date brings no purchases and 4 sales.
Most recently, on 8 March 2023, the filings show an open-market sale worth €9,911 in Arcutis Biotherapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to David W. Osborne
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 690 shares@ US$15.26347.6% of flowCommon StockSEC:0001567619-23-004668:0
- 14,900 shares0Common StockSEC:0001567619-23-004545:0
- 792 shares@ US$16.16639.2% of flowCommon StockSEC:0001567619-23-004268:0
- 2,197 shares@ US$25.414442.1% of flowCommon StockSEC:0001567619-22-013925:0
- 2,197 shares@ US$20.424331.7% of flowCommon StockSEC:0001567619-22-008817:0
- 13,300 shares0Common StockSEC:0001567619-22-006492:0
- 775 shares@ US$17.75279.4% of flowCommon StockSEC:0001567619-22-006229:0
7 of 7 declarations
